Leveraging the Genetics of Human Resilience to Restore Microglial Homeostasis Through CD33-targeting RNA Therapeutics
- How protective human genetic variants provide a blueprint for discovering genetically validated targets across ALS, FTD, PD, and Alzheimer’s disease
- Exploring the known and unknown roles of the innate immune system in the progression of age-related neurodegeneration
- Demonstrating therapeutic targeting of CD33 can be employed in several neurodegenerative diseases to reduce pathologic neuroinflammation
- The translational importance of genetically informed targets and biomarker-driven development for advancing next-generation therapies for neurodegeneration